BIOLIGHT(SZ:300246) Sou Hu Cai Jing·2025-07-29 15:22Core Viewpoint - Baolait (300246) experienced a decline in stock price, closing at 9.46 yuan, with a trading volume of 1.63 billion yuan and a significant net outflow of funds [1] Financial Performance - For Q1 2025, Baolait reported total revenue of 248 million yuan, a year-on-year decrease of 7.17% - The net profit attributable to shareholders was 14.45 million yuan, showing a substantial year-on-year increase of 298.35% - The non-recurring net profit was 338,800 yuan, reflecting a year-on-year growth of 105.49% - The current ratio stood at 2.278, the quick ratio at 1.856, and the debt-to-asset ratio at 45.06% [1] Company Background - Guangdong Baolait Medical Technology Co., Ltd. was established in 1993 and is located in Zhuhai City - The company focuses on research and experimental development, with a registered capital of 2.6368 billion yuan [1] - The legal representative of the company is Yan Jinyuan [1] Investment and Intellectual Property - Baolait has invested in 21 companies and participated in 946 bidding projects - The company holds 58 trademark registrations and 327 patents, along with 179 administrative licenses [2]